Compare Nutrien Ltd (NTR) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Twist Bioscience Corp — how do they compare? Nutrien Ltd trades at $80.95 (market cap $38.47B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Nutrien Ltd is far larger — about 4.6× Twist Bioscience Corp's market cap, and Nutrien Ltd pays a 2.73% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| NTR | TWST | |
|---|---|---|
Market Cap | $38.47B | $8.42B |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $153.10 |
52-Week Low | $53.64 | $24.16 |
Enterprise Value | $50.28B | $8.35B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $80.68, up 1.52% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q2 2026 earnings, missing EPS estimates but beating on revenue, driven by higher fertilizer prices. Analyst consensus is a Moderate Buy with a $76.17 price target, though recent news includes a downgrade to Hold citing cost pressures and volume constraints. Cash flow trends show consistent operational strength but negative net cash flow in recent years.
The outlook is cautiously optimistic, supported by strong potash and nitrogen demand and institutional buying, but risks include cyclical earnings, rising sulfur costs, and volatile agricultural markets. The stock's current price above the consensus target suggests limited near-term upside, requiring monitoring of cost management and volume recovery for sustained growth.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
